Shilpa Medicare Limited Share Price & Analysis
₹640▲ +2.33%Updated 21 Jul 2026, 05:01 pm IST
LTP
₹640
+2.33%
Open
₹—
High
₹642
Low
₹615.2
Close
₹640
52W High
₹650
52W Low
₹260
Volume
508K
Lot Size
1
Sector
Healthcare
Market Cap
₹12K Cr
Face Value
₹1
Mid Cap
Price Chart
Fundamentals
P/E
52
Sector P/E
54.4
P/B
4.16
EPS
₹12.43
ROE
9.4%
ROCE
11%
D/E Ratio
0.25
Div Yield
0.08%
Book Value
₹132
+
Strengths
- ✓Low debt relative to equity (D/E 0.3x)
−
Concerns
- ✗Trading near 52-week high (₹650)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
SHILPAMED · as of Mar 2026
Promoters44.23%
FII10.97%▲1.07
DII7.55%▼0.72
Public37.25%▼0.34
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 50.01% | 50.01% | 44.39% | 44.33% | 44.23% | 44.23% |
| FII | 8.52% | 5.63% | 9.08% | 9.59% | 9.90% | 10.97% |
| DII | 0.06% | 1.65% | 7.61% | 8.18% | 8.27% | 7.55% |
| Public | 41.41% | 42.71% | 38.91% | 37.90% | 37.59% | 37.25% |
Corporate Events
Bonus 1:1
Bonus2 Oct 2025
Dividend - Re 1 Per Share
Dividend16 Sept 2025
Annual General Meeting
AGM5 Sept 2024
Annual General Meeting
AGM21 Sept 2023
Latest News
All news →Shilpa Medicare Bengaluru unit fails USFDA inspection
*Shilpa Medicare Bengaluru unit fails USFDA inspection* — The company's Bengaluru facility has received **5 observations** following a USFDA pre-approval inspection (PAI), signaling potential delays in product approvals. This regulatory setback could impact export plans and investor sentiment. Immediate corrective actions may be required to address compliance issues. 📊 *STOCKS:* SHILPAM | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #USFDA
Medical Dialogues1 Jun
Shilpa Biologicals signs co-development deal with Finland's Orion
*Shilpa Biologicals signs co-development deal with Finland's Orion* Shilpa Biologicals Pvt Ltd, a wholly owned subsidiary of Shilpa Medicare, has entered into a co-development and supply agreement with Orion Corporation of Finland. The partnership focuses on advancing and supplying pharmaceutical products. This strategic move enhances Shilpa's global footprint and R&D capabilities. 📊 *STOCKS:* SHILPAMED | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #pharma
NSE Filing30 Jun
Shilpa Medicare commissions ADC manufacturing facility via subsidiary
*Shilpa Medicare commissions ADC manufacturing facility via subsidiary*. A state-of-the-art GMP facility for Antibody Drug Conjugates has been commissioned by Shilpa Biologicals, a material subsidiary. This marks a strategic expansion into high-value biopharma products. The move strengthens its footprint in the global specialty pharmaceuticals market. 📊 *STOCKS:* SHILPAMED | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #ADC
NSE Filing24 Jun
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹437 Cr ▲6.6% | ₹410 Cr ▲10.8% | ₹370 Cr ▲15.3% | ₹321 Cr ▼3.0% | ₹331 Cr ▲3.8% | ₹319 Cr ▼7.3% | ₹344 Cr ▲17.4% | ₹293 Cr |
| Op. Profit | ₹120 Cr ▲5.3% | ₹114 Cr ▲5.6% | ₹108 Cr ▲18.7% | ₹91 Cr ▲15.2% | ₹79 Cr ▼2.5% | ₹81 Cr ▼5.8% | ₹86 Cr ▲22.9% | ₹70 Cr |
| OPM | 27.0% ▼3.6% | 28.0% ▼3.4% | 29.0% ▲3.6% | 28.0% ▲16.7% | 24.0% ▼4.0% | 25.0% ▲0.0% | 25.0% ▲4.2% | 24.0% |
| Net Profit | ₹108 Cr ▲140.0% | ₹45 Cr ▲2.3% | ₹44 Cr ▼6.4% | ₹47 Cr ▲213.3% | ₹15 Cr ▼53.1% | ₹32 Cr ▲77.8% | ₹18 Cr ▲28.6% | ₹14 Cr |
| EPS (₹) | 5.51 ▲141.7% | 2.28 ▲1.3% | 2.25 ▼6.2% | 2.4 ▲224.3% | 0.74 ▼54.3% | 1.62 ▲76.1% | 0.92 ▲27.8% | 0.72 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1.5K Cr ▲20.1% | ₹1.3K Cr ▲11.8% | ₹1.1K Cr ▲9.6% | ₹1.0K Cr ▼8.3% | ₹1.1K Cr ▲26.9% | ₹899 Cr ▼1.0% | ₹908 Cr ▲23.9% | ₹733 Cr ▼7.1% | ₹789 Cr ▲1.3% | ₹779 Cr |
| Expenses | ₹1.1K Cr ▲14.4% | ₹965 Cr ▲6.4% | ₹907 Cr ▼4.2% | ₹947 Cr ▲0.7% | ₹940 Cr ▲30.9% | ₹718 Cr ▲4.4% | ₹688 Cr ▲17.6% | ₹585 Cr ▼7.7% | ₹634 Cr ▲3.3% | ₹614 Cr |
| Op. Profit | ₹435 Cr ▲37.7% | ₹316 Cr ▲32.2% | ₹239 Cr ▲141.4% | ₹99 Cr ▼51.0% | ₹202 Cr ▲11.6% | ₹181 Cr ▼17.4% | ₹219 Cr ▲48.0% | ₹148 Cr ▼4.5% | ₹155 Cr ▼6.1% | ₹165 Cr |
| OPM | 28.0% ▲12.0% | 25.0% ▲19.0% | 21.0% ▲133.3% | 9.0% ▼50.0% | 18.0% ▼10.0% | 20.0% ▼16.7% | 24.0% ▲20.0% | 20.0% ▲0.0% | 20.0% ▼4.8% | 21.0% |
| Other Income | ₹39 Cr ▲880.0% | ₹-5 Cr ▼133.3% | ₹15 Cr ▼11.8% | ₹17 Cr ▼19.0% | ₹21 Cr ▼76.7% | ₹90 Cr ▲429.4% | ₹17 Cr ▼48.5% | ₹33 Cr ▲50.0% | ₹22 Cr ▲46.7% | ₹15 Cr |
| Interest | ₹59 Cr ▼22.4% | ₹76 Cr ▼17.4% | ₹92 Cr ▲55.9% | ₹59 Cr ▲43.9% | ₹41 Cr ▲86.4% | ₹22 Cr ▲340.0% | ₹5 Cr ▲25.0% | ₹4 Cr ▲33.3% | ₹3 Cr ▲0.0% | ₹3 Cr |
| Depreciation | ₹120 Cr ▲6.2% | ₹113 Cr ▲4.6% | ₹108 Cr ▲12.5% | ₹96 Cr ▲20.0% | ₹80 Cr ▲48.1% | ₹54 Cr ▲22.7% | ₹44 Cr ▲4.8% | ₹42 Cr ▲13.5% | ₹37 Cr ▲19.4% | ₹31 Cr |
| PBT | ₹295 Cr ▲141.8% | ₹122 Cr ▲125.9% | ₹54 Cr ▲242.1% | ₹-38 Cr ▼137.3% | ₹102 Cr ▼47.7% | ₹195 Cr ▲3.7% | ₹188 Cr ▲38.2% | ₹136 Cr ▼0.7% | ₹137 Cr ▼6.2% | ₹146 Cr |
| Tax % | 18.0% ▼50.0% | 36.0% ▼12.2% | 41.0% ▲315.8% | -19.0% ▼146.3% | 41.0% ▲64.0% | 25.0% ▲38.9% | 18.0% ▼5.3% | 19.0% ▼24.0% | 25.0% ▼13.8% | 29.0% |
| Net Profit | ₹243 Cr ▲211.5% | ₹78 Cr ▲143.8% | ₹32 Cr ▲203.2% | ₹-31 Cr ▼150.8% | ₹61 Cr ▼58.2% | ₹146 Cr ▼5.8% | ₹155 Cr ▲40.9% | ₹110 Cr ▲6.8% | ₹103 Cr ▼1.0% | ₹104 Cr |
| EPS (₹) | 12.44 ▲211.0% | 4 ▲117.4% | 1.84 ▲198.4% | -1.87 ▼153.6% | 3.49 ▼61.5% | 9.06 ▼5.3% | 9.57 ▲39.1% | 6.88 ▲6.7% | 6.45 ▼3.9% | 6.71 |
| Div Payout | 5.0% ▼58.3% | 12.0% | 0.0% | 0.0% ▼100.0% | 16.0% ▲166.7% | 6.0% ▲0.0% | 6.0% ▼14.3% | 7.0% ▲40.0% | 5.0% ▲25.0% | 4.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹20 Cr ▲100.0% | ₹10 Cr ▲11.1% | ₹9 Cr ▲0.0% | ₹9 Cr ▲0.0% | ₹9 Cr ▲12.5% | ₹8 Cr ▲0.0% | ₹8 Cr ▲0.0% | ₹8 Cr ▲0.0% | ₹8 Cr ▲0.0% | ₹8 Cr |
| Reserves | ₹2.6K Cr ▲8.9% | ₹2.4K Cr ▲31.2% | ₹1.8K Cr ▲1.4% | ₹1.8K Cr ▼2.1% | ₹1.8K Cr ▲23.3% | ₹1.5K Cr ▲11.4% | ₹1.3K Cr ▲11.1% | ₹1.2K Cr ▲10.4% | ₹1.1K Cr ▲10.0% | ₹979 Cr |
| Borrowings | ₹660 Cr ▲12.2% | ₹588 Cr ▼37.2% | ₹937 Cr ▲17.4% | ₹798 Cr ▲16.8% | ₹683 Cr ▼19.3% | ₹846 Cr ▲116.9% | ₹390 Cr ▲101.0% | ₹194 Cr ▲1.6% | ₹191 Cr ▼20.7% | ₹241 Cr |
| Other Liabilities | ₹455 Cr ▲29.6% | ₹351 Cr ▲1.2% | ₹347 Cr ▲7.4% | ₹323 Cr ▼12.7% | ₹370 Cr ▲20.1% | ₹308 Cr ▲14.1% | ₹270 Cr ▲23.9% | ₹218 Cr ▼2.2% | ₹223 Cr ▼8.6% | ₹244 Cr |
| Total Liabilities | ₹3.7K Cr ▲11.9% | ₹3.3K Cr ▲7.0% | ₹3.1K Cr ▲6.5% | ₹2.9K Cr ▲1.0% | ₹2.9K Cr ▲9.3% | ₹2.6K Cr ▲32.3% | ₹2.0K Cr ▲23.5% | ₹1.6K Cr ▲7.4% | ₹1.5K Cr ▲1.8% | ₹1.5K Cr |
| Assets | ||||||||||
| Fixed Assets | ₹2.0K Cr ▲44.3% | ₹1.4K Cr ▲2.4% | ₹1.4K Cr ▲1.2% | ₹1.4K Cr ▲1.9% | ₹1.3K Cr ▲20.8% | ₹1.1K Cr ▲70.9% | ₹650 Cr ▲16.5% | ₹558 Cr ▲4.5% | ₹534 Cr ▲8.5% | ₹492 Cr |
| CWIP | ₹431 Cr ▼47.6% | ₹822 Cr ▲14.3% | ₹719 Cr ▲9.8% | ₹655 Cr ▲29.4% | ₹506 Cr ▼6.5% | ₹541 Cr ▼18.8% | ₹666 Cr ▲55.2% | ₹429 Cr ▲104.3% | ₹210 Cr ▲48.9% | ₹141 Cr |
| Investments | ₹58 Cr ▲65.7% | ₹35 Cr ▼12.5% | ₹40 Cr ▼7.0% | ₹43 Cr ▲26.5% | ₹34 Cr ▲61.9% | ₹21 Cr ▲110.0% | ₹10 Cr ▲400.0% | ₹2 Cr ▼98.6% | ₹140 Cr ▼44.7% | ₹253 Cr |
| Other Assets | ₹1.2K Cr ▲12.8% | ₹1.0K Cr ▲9.2% | ₹950 Cr ▲13.4% | ₹838 Cr ▼15.6% | ₹993 Cr ▲3.5% | ₹959 Cr ▲44.9% | ₹662 Cr ▲6.6% | ₹621 Cr ▲1.0% | ₹615 Cr ▲4.8% | ₹587 Cr |
| Total Assets | ₹3.7K Cr ▲11.9% | ₹3.3K Cr ▲7.0% | ₹3.1K Cr ▲6.5% | ₹2.9K Cr ▲1.0% | ₹2.9K Cr ▲9.3% | ₹2.6K Cr ▲32.3% | ₹2.0K Cr ▲23.5% | ₹1.6K Cr ▲7.4% | ₹1.5K Cr ▲1.8% | ₹1.5K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹342 Cr ▲159.1% | ₹132 Cr ▼3.6% | ₹137 Cr ▼23.9% | ₹180 Cr ▲71.4% | ₹105 Cr ▲123.4% | ₹47 Cr ▼62.1% | ₹124 Cr ▼15.6% | ₹147 Cr ▲226.7% | ₹45 Cr ▲21.6% | ₹37 Cr |
| Investing CF | ₹-326 Cr ▼64.6% | ₹-198 Cr ▼15.8% | ₹-171 Cr ▲26.3% | ₹-232 Cr ▲18.9% | ₹-286 Cr ▲29.2% | ₹-404 Cr ▼39.3% | ₹-290 Cr ▼48.0% | ₹-196 Cr ▼1860.0% | ₹-10 Cr ▲96.1% | ₹-257 Cr |
| Financing CF | ₹14 Cr ▼77.8% | ₹63 Cr ▲34.0% | ₹47 Cr ▲2.2% | ₹46 Cr ▼44.6% | ₹83 Cr ▼81.0% | ₹436 Cr ▲147.7% | ₹176 Cr ▲1660.0% | ₹10 Cr ▲116.4% | ₹-61 Cr ▼119.5% | ₹313 Cr |
| Net Cash Flow | ₹30 Cr ▲1100.0% | ₹-3 Cr ▼123.1% | ₹13 Cr ▲285.7% | ₹-7 Cr ▲92.9% | ₹-98 Cr ▼224.1% | ₹79 Cr ▲690.0% | ₹10 Cr ▲125.6% | ₹-39 Cr ▼50.0% | ₹-26 Cr ▼128.0% | ₹93 Cr |
| Free Cash Flow | ₹-15 Cr ▲86.5% | ₹-111 Cr ▼131.3% | ₹-48 Cr ▼4.3% | ₹-46 Cr ▲79.6% | ₹-226 Cr ▲25.2% | ₹-302 Cr ▼37.3% | ₹-220 Cr ▼45.7% | ₹-151 Cr ▼64.1% | ₹-92 Cr ▼16.5% | ₹-79 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 123d ▼2.4% | 126d ▲0.8% | 125d ▲10.6% | 113d ▼8.9% | 124d ▲40.9% | 88d ▼11.1% | 99d ▼2.0% | 101d ▼1.0% | 102d ▲27.5% | 80d |
| Inventory Days | 291d ▼5.8% | 309d ▲0.0% | 309d ▲10.4% | 280d ▼17.2% | 338d ▼20.8% | 427d ▲43.3% | 298d ▲12.0% | 266d ▲37.1% | 194d ▲3.7% | 187d |
| Days Payable | 113d ▲32.9% | 85d ▼45.5% | 156d ▲24.8% | 125d ▼10.1% | 139d ▲52.7% | 91d ▼25.4% | 122d ▲6.1% | 115d ▲8.5% | 106d ▼3.6% | 110d |
| Cash Conv. Cycle | 301d ▼14.0% | 350d ▲25.9% | 278d ▲3.7% | 268d ▼17.0% | 323d ▼24.0% | 425d ▲54.5% | 275d ▲8.7% | 253d ▲33.9% | 189d ▲20.4% | 157d |
| Working Capital Days | 51d ▼37.0% | 81d ▲68.8% | 48d ▲469.2% | -13d ▼116.9% | 77d ▲6.9% | 72d ▲5.9% | 68d ▼30.6% | 98d ▲0.0% | 98d ▲24.1% | 79d |
| ROCE | 11.0% ▲37.5% | 8.0% ▲60.0% | 5.0% ▲400.0% | 1.0% ▼83.3% | 6.0% ▼25.0% | 8.0% ▼33.3% | 12.0% ▲33.3% | 9.0% ▼10.0% | 10.0% ▼28.6% | 14.0% |
Source: Screener.in · Lower days = better efficiency
Related Analysis
Frequently Asked Questions
What is Shilpa Medicare Limited share price today?▾
Shilpa Medicare Limited (SHILPAMED) is currently trading at ₹640 on NSE, up 2.33% as of the last market session. Prices update daily after market close on MarketNetra.
Is Shilpa Medicare Limited available in F&O (Futures & Options)?▾
Yes, Shilpa Medicare Limited (SHILPAMED) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Shilpa Medicare Limited 52-week high and low?▾
Shilpa Medicare Limited's 52-week high is ₹650 and the 52-week low is ₹260. The current price of ₹640 is 1.5% below the 52W high.
What is Shilpa Medicare Limited P/E ratio?▾
Shilpa Medicare Limited's current P/E ratio is 52. This indicates the market is paying ₹52 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Shilpa Medicare Limited options?▾
Shilpa Medicare Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade SHILPAMED options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.